An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Yang, James C ^a,b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Building 10 ^*  (United States)

Author keywords

Cytokine; Immunotherapy; Interleukin 2; Randomized clinical trial; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0031415591     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
2. Mule JJ, Yang JC, Afreniere RL et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987;139:285-294.
3. Atkins M, Sparano J, Fisher R et al. Randomized phase II trial of high-dose interleukin-2 alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11: 661-670.
4. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus imerleukin-2. JAMA 1994;271:907-913.
5. Dillman RO, Oldham RK, Tauer KW et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991;9: 1233-1240.
6. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865-2875.
7. Caligiuri MA, Murray C, Soiffer RJ et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9:2110-2119.
8. Atzpodien J, Korfer A, Evers P et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 1990;2:18-26.
9. Sleijfer DT, Janssen RAJ, Buter J et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.
10. Konrad MW, Hemstreet G, Hersh EM et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50: 2009-2017.
11. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.